My experience is retail investors in biotech in Australia are the least fickle and the most willing to put in the effort to understand what a company is about. I have spoken to hundreds of Australian institutional investors over the years and very few have any interest or understanding of biotech. The huge investor gap we have here in Australia is in the long term focused institutional investors who are interested in biotech - in the USA there are thousands, but in Australia less than a handful.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-190
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |